Online inquiry

IVTScrip™ mRNA-Anti-MCAM, PRX-003(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13542MR)

This product GTTS-WQ13542MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets MCAM gene. The antibody can be applied in Psoriasis research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_006500.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4162
UniProt ID P43121
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MCAM, PRX-003(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13542MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15749MR IVTScrip™ mRNA-Anti-SEMA4D, VX-15(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA VX-15
GTTS-WQ4972MR IVTScrip™ mRNA-Anti-GP, c2G4-N(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA c2G4-N
GTTS-WQ2718MR IVTScrip™ mRNA-Anti-CD19&CD3E, AMG103(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG103
GTTS-WQ5465MR IVTScrip™ mRNA-Anti-tcdB, CDB-1(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CDB-1
GTTS-WQ5925MR IVTScrip™ mRNA-Anti-CD274, CK-301(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CK-301
GTTS-WQ3707MR IVTScrip™ mRNA-Anti-MSLN, BAY 94-9343(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BAY 94-9343
GTTS-WQ7948MR IVTScrip™ mRNA-Anti-ICOS, GSK-3359609(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GSK-3359609
GTTS-WQ15085MR IVTScrip™ mRNA-Anti-TNC, ST2146(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ST2146
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW